Ginkgo Bioworks Holdings (DNA) EBIT (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported EBIT for 7 consecutive years, with -$58.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 0.66% year-over-year to -$58.5 million; the trailing twelve-month figure through Jun 2026 stood at -$290.7 million (up 2.43% YoY), and the FY2025 full-year result was -$315.3 million, up 43.68% from the prior year.
• EBIT grew to -$58.5 million in Q2 2026 per DNA's latest filing, from -$71.4 million in the prior quarter.
• Across five years, EBIT topped out at -$55.2 million in Q3 2024 and bottomed at -$675.4 million in Q1 2022.
• Historically, EBIT has averaged -$225.7 million across 5 years, with a median of -$178.1 million in 2023.
• The widest YoY moves for EBIT: up 86.3% in 2022, down 2355.53% in 2022.
• Over 5 years, EBIT stood at -$230.9 million in 2022, then gained by 22.85% to -$178.1 million in 2023, then surged by 41.83% to -$103.6 million in 2024, then surged by 31.71% to -$70.8 million in 2025, then climbed by 17.25% to -$58.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$58.5 million, -$71.4 million, and -$70.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.